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Abstract
Cardiovascular disease is multifactorial. The main risk factors for 
developing cardiovascular disease (age, sex, smoking, diabetes, 
hyperlipidaemia and hypertension) do not explain its development in 
everyone. New risk factors are continually being sought in order to better 
understand and treat the disease process. In recent years homocysteine has 
been proposed as a risk factor for the development of premature 
cardiovascular disease as a consequence of the accelerated arterial and 
venous thrombotic disease seen in homocystinuria as a result of a single 
gene defect. This theory has been difficult to test because patients with 
premature cardiovascular disease are thankfully rare and because of the 
difficulties in measuring homocysteine itself.
We propose that, if homocysteine is a causative risk factor for 
atherothrombosis, it will be involved in the development of cardiovascular 
disease regardless of age and have therefore studied affected patients from 
routine hospital clinics. Homocysteine analysis has become easier over the 
past decade with the development of HPLC methods utilising fluorescent 
detection, but these methods involve toxic chemicals and suffer from high 
background fluoresence. I have developed an HPLC method more suited to a 
routine hospital laboratory utilising coulometric detection for measuring 
plasma total homocysteine and used it to investigate the relationship 
between homocysteine levels and both micro- and macro-vascular 
atherothrombotic disease.
Retinal vessel occlusion was chosen as the paradigm for 
microvascular disease and the homocysteine levels were found to be higher 
in 70 patients with retinal artery or vein occlusion than controls, (18.4 v 9.5 
pmol/l; p = 0.0002, for arterial occlusions) and (13.8 v 9.5 ^mol/l; p < 0.0001, 
for venous occlusions). Multivariate analysis confirmed the link between 
homocysteine and retinal vein occlusion with a mean 32% increase (95% 
confidence intervals, 14% -  52%; p = 0.0002) in homocysteine levels in the 
subjects compared to controls. This is the first time that homocysteine has 
been linked to microvascular disease and it is possible that B vitamins may 
be of use in the prevention of further occlusions.
Homocysteine levels were also significantly elevated in unselected 
patients with peripheral vascular disease (PVD) attending vascular clinics in 
the Midlands. (17.4 v 12.3 pmol/l, p < 0.01). Logistic regression analysis 
confirmed the link between PVD and homocysteine with an odds ratio 
favouring PVD of 4.1 (95% Cl, 1 .5 -11 .1 ) per p.mol/1 homocysteine increase 
over the mean. These results confirm that homocysteine appears to be 
strongly linked to peripheral vascular disease regardless of age.
Two hundred and eighty patients undergoing coronary angiography were 
recruited from a Chest Pain clinic. Homocysteine levels were significantly 
elevated in patients with ischaemic heart disease compared to the controls 
(11.5 V 10.1 p.mol/1, p = 0.008). Homocysteine levels were linked to 
myocardial infarction in females (11.9 v 9.4 jumol/l, p = 0.016), but not males 
(11.1 V 10.9 pmol/l, p = 0.72); nor were they linked to angina in either sex. 
Logistic regression analysis confirmed that a 1 jumol/l increase in 
homocysteine resulted in an odds ratio for ischaemic heart disease of 1.5
Ill
(95% Cl, 1 .03-55 .2 , p = 0.019) for both sexes and 1.3 (95% Cl, 1 .04-35.4 ; 
p = 0.033) for females. Only total cholesterol was significantly linked to 
ischaemic heart disease in males. These findings suggest that homocysteine 
may be a more important risk factor for ischaemic heart disease in females 
than males. Most previous studies have concentrated on men and the 
outcomes of prospective studies have been largely negative. These findings 
suggest that future prospective studies of homocysteine and IHD should 
include more women.
The mechanism by which homocysteine causes athero-thrombosis is 
unclear. One theory is that the thiol group is involved in free radical 
formation. The literature, however, is divided between those who find 
homocysteine to be a pro-oxidant and those who find homocysteine to be an 
antioxidant. I found that physiological concentrations of homocysteine added 
to freshly prepared lipoproteins markedly prolonged the lag phase for 
conjugated diene formation (and therefore acted as an antioxidant).
Repetition of the experiment after ageing the lipoproteins overnight at +4°C 
showed that homocysteine acted as a pro-oxidant. We believe that oxidation 
of the thiol group keeps the antioxidant vitamin E reduced while the 
lipoproteins are fresh, but once the vitamin E is exhausted, homocysteine 
oxidation generates oxygen free radicals. This would also help to explain why 
the literature on the subject is equivocal.
Hyperhomocysteinaemia is readily treated by low doses of folate and 
vitamin B12. I investigated the effects of folate supplementaion on lipoprotein 
oxidation in a group of volunteers from the top (04) and bottom (01) quartiles 
of the homocysteine reference interval. The subjects in 04, were given 400
IV
pg of folate dally for 4 weeks, whilst the others were not treated. 
Homocysteine levels fell by 23% in the treatment group as expected, and the 
lag phase for conjugated diene formation increased, significantly, by 33%, 
while the control group's homocysteine levels and lag phases did not change 
over the course of the investigation. This pilot study builds on the knowledge 
that folate reduces homocysteine levels to imply that this also has an effect 
on the oxidisation of low-density lipoproteins. A larger study is planned to 
explore the possibility of inexpensive B vitamin treatment for 
atherothrombotic disease.
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Introduction
Atherosclerosis, and its complication thrombosis (athero-thrombosis), 
is the largest cause of morbidity and mortality in the UK. It is a multifactorial 
disease with hundreds of identified risk factors. Despite this, only about half 
of athero-thrombotic disease can be explained by the well-established risk 
factors of smoking, age, gender, hyperlipidaemia. hypertension and diabetes 
meliitus. Hyperhomocysteinaemia has been proposed as an additional 
independent risk factor for athero-thrombotic disease^ however, this has not 
yet been fully established. If a causative relationship between 
hyperhomocysteinaemia and vascular disease was proved, treatment with B 
group vitamins might provide a safe and inexpensive treatment.
Homocysteine (HCySH) is a thiol-containing amino acid and an 
intermediary metabolite in methionine metabolism (Figure 1). It arises from 
the déméthylation of S-adenosyl methionine and either undergoes 
remethylation to methionine, a process dependent on folic acid (as 
methylene tetrahydrofolate) and vitamin B12. or in the presence of excess 
methionine, enters the trans-sulphuration pathway. Here it is converted to 
cysteine, and may be further metabolised to CO2, NH4, H2O and SO4. The 
rate-limiting enzyme in this pathway, cystathionine p-synthase, is dependent 
on pyridoxine, vitamin Be, as cofactor. Unlike methionine and cysteine, 
homocysteine is not a constituent of proteins and only a small amount enters 
the circulation, where the highly reactive thiol group forms disulphide bonds 
with other thiol-containing molecules, primarily albumin (-70%). Less than 
1% of the total plasma homocysteine circulates in its free form^.
Figure 1
The Methionine Cycle
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Homocysteine is the de-methylation product of methionine. Methionine is 
activated by reaction with adenosine triphosphate to produce the high-energy 
intermediate, S-adenosyl methionine, which can donate methyl groups to 
nucleic acids and proteins. Homocysteine can either be metabolised to 
cysteine (Trans-sulphuration pathway) or remethylated to methionine 
(Remethylation pathway). Both pathways involve vitamins (shown in red) Be = 
pyridoxine; B12 = cobalamin; THF = tetrahydrofolate.
Homocysteine is eventually metabolised by the kidney^. Normal adultjevels 
for plasma total HCySH are between 5 & 15 increasing with age. 
Interest in HCySH as a risk factor for atherothrombotic disease has arisen 
because children born with homocystinuria, an inherited metabolic disease 
resulting in plasma HCySH levels being elevated above 100 i^M, die in early 
adulthood from widespread arterial and venous thromboses'^. It was 
proposed that homocysteine was the direct cause of this outcome®, as there 
were no other biochemical abnormalities to account for the athero­
thrombosis. Skeletal abnormalities, mental retardation and tens dislocation 
are also associated with classical homocystinuria. The defective enzyme is 
cystathionine p-synthase, which is the rate-limiting enzyme in the trans- 
sulphuration pathway. Treatment with the enzyme’s cofactor, pyridoxine, 
ameliorates the condition in many patients, and is the primary treatment. 
Defects in the remethylation pathway have also occasionally been described, 
which result in similar syndromes to classical homocystinuria.
The situation is different in adults, where folate and/or vitamin B12 
deficiencies are thought to underlie more moderate degrees of 
hyperhomocysteinaemia (1 5 -1 0 0  p,M). Studies show that supplements of 
400 pg of folic acid daily can reduce fasting total HCySH levels by up to 30%, 
while vitamin B12 produces a smaller fall (< 10%), but pyridoxine has little 
effect^. This suggests that borderline folate deficiency may be common, and 
that the remethylation pathway is likely to be more important than 
cystathionine p-synthase defects in the pathogenesis of adult 
hyperhomocystinaemia^.
There have been numerous cross-sectional studies linking 
hyperhomocysteinaemia with stroke^ ®, peripheral vascular disease 
(PVD)^’^ ’®, deep venous thrombosis®''’  ^and ischaemic heart disease 
(IHD)^'^^'^^. The results of prospective studies have been less conclusive, 
with most studies failing to detect any relationship between HCySH and 
athero-thrombosis^®"^®.
Cross-sectional studies^ have concentrated on the rare cases of 
premature vascular disease (onset before the age of 60) as heterozygotes for 
homocystinuria were believed to be at increased risk of athero-thrombotic 
disease since it was assumed that their plasma HCySH levels would be 
moderately elevated. This is a dubious proposition for two reasons. First, 
classical homocystinuria is due to a defect in the trans-sulphuration pathway, 
yet adult hyperhomocystinaemia seems to be associated with defects in the 
remethylation pathway. Moderate hyperhomocysteinaemia is associated 
with borderline B vitamin deficiency, which becomes more prevalent with 
age^®. Second, there is no evidence that relatives of children with 
homocystinuria are at increased risk of developing athero-thrombotic 
disease^^.
Another problem with many published studies is that they report 
plasma homocysteine concentrations following methionine loading, either 
alone or in combination with fasting homocysteine levels^’®’®’®. Methionine 
loading tests are unstandardised, unphysiological and are also impractical for 
most large-scale studies. Classification of hyperhomocystinaemia from 
methionine loading usually differs from classification based on fasting 
homocysteine levels. This discrepancy in the definition of
hyperhomocystinaemia has hindered the investigation of the underlying 
pathophysiology.
There can be little doubt that HCySH does cause the athero- 
thrombotic disease in classical homocystinuria. If hyperhomocysteinaemia is 
a risk factor for athero-thrombosis in the general population, then it will be 
apparent in the general clinic population and it will almost certainly be due to 
a defect in the remethylation pathway, causing elevated fasting plasma 
homocysteine concentrations.
The measurement of HCySH has been technically difficult and 
although the link with athero-thrombotic disease was proposed by McCully 
over thirty years ago®, it is only in the last decade that HPLC methods for the 
assay of HCySH have made clinical studies practicable. Previous techniques, 
such as amino acid analysis, have lacked the sensitivity to measure 
homocysteine concentrations in the normal population and researchers had 
to resort to methionine loading to stress the methionine cycle and ensure 
plasma homocysteine levels fell within the analytical range of their 
methodology. Recent studies have measured total plasma homocysteine 
after a 12 hour overnight fast, which allows standardisation on a 
reproducible, physiological measurement.
Most commonly available HPLC detection methods utilise fluorescent 
labelling of the thiol group of HCySH, but the drawbacks are high background 
fluorescence and the use of hazardous chemicals (fiuorophores, sodium 
tetrahydroborate, mercaptoethanoi). This has restricted the availability of the 
assay. I perceived a need for a new method utilising the HPLC equipment
and expertise readily available in NHS Clinical Biochemistry laboratories, 
which could be easily introduced into routine service.
Various theories have been proposed to account for the atherogenicity 
of homocysteine. Endothelial toxicity^®, procoagulant effect on coagulation 
factors"*®, or free radical generation®®'^\ Most of the studies have been 
conducted at non-physiological homocysteine concentrations and the results 
are therefore unreliable. A particular interest of our Clinical Biochemistry 
department has been oxidative stress and free radical formation, I therefore 
chose to study HCySH and lipoprotein oxidation as a mechanism to explain 
the link between HCySH and atherosclerosis.
I set out to develop a novel HPLC assay for HCySH and use it to 
investigate the relationship between hyperhomocysteinaemia and athero- 
thrombotic disease in older, more typical, hospital clinic populations. I also 
investigated whether HCySH was linked to microvascular disease, as all 
previous studies have concentrated on macrovascular disease, and 
experimented with the effects of HCySH on lipoprotein oxidation to gain an 
understanding of the potential effects of hyperhomocystinaemia.
Materials and Methods 
Subjects
All of the patient studies in this thesis had been approved by the 
relevant hospital ethics committee and all patients gave prior informed 
consent. Details of any power calculations and the specific inclusion or 
exclusion criteria are given in connection with each study.
Analyses
Homocysteine was analysed by reversed-phase, ion-pair HPLC with 
electrochemical detection as described in detail below. Other analytes were 
measured by routine laboratory methods using commercially available 
reagents, as described in the relevant section. Quality control was ensured 
by internal and, when available, external QC schemes.
Lipoprotein ultracentrifugation was performed on EDTA plasma. A fraction 
containing LDL was isolated by density gradient ultracentrifugation using a 
Centrikon T1065 centrifuge (Kontron Instruments, Watford, UK) with a swing 
out rotor (TST 55.5) and 5 ml polyallomer tubes. Plasma (3 ml) was mixed 
with 1 ml 1.182 kg/I density solution (2.4 mol/1 NaBr in 1.006 kg/l density 
solution) and overlaid with 0.5 ml 1.006 kg/l density solution (0.193 mol/l 
NaCI, 1 mmol/l NaOH and 0.25 mmol/l EDTA) in the centrifuge tubes. These 
were centrifuged at 40,000 rpm for 18 hours at 15°C. The orange band 
containing LDL was aspirated in a volume of less than 0.5 ml. Samples were 
run in duplicate and the LDL fractions combined. The lipoproteins were 
further purified from EDTA, water soluble antioxidants e.g. urate and other 
low molecular weight contaminants by gel filtration chromatography using
PD-10 columns (Pharmacia Ltd, Milton Keynes, UK). Fractions of 0.5 ml were 
collected following elution with phosphate buffered saline (PBS), pH 7.4.
LDL containing fractions (identified by orange / brown coloration) were 
pooled.
LDL Oxidation
The copper (II) [Cu (II)] catalysed oxidation of LDL was monitored by 
measuring the change in absorbance at 234 nm in a Philips Unicam 
automatic eight position changer spectrophotometer. Absorbance readings 
were taken every 3 minutes over a three hour period. The output from the 
spectrophotometer was entered into an Excel spreadsheet. LDL (final 
concentration 50 mg/l) was added to a quartz cuvette and incubated in PBS 
at 37°C in the presence of 10 inmol/l copper sulphate. A negative control 
without added copper ions or thiol was included in every experiment.
Statistics
Homocysteine and lipoprotein (a) levels were log-transformed before 
statistical analysis to normalise the data. Univariate analyses used the 
Microsoft Excel and Astute software packages. Multivariate analysis was by 
SPSS for Windows. Lag times for lipoprotein oxidation were compared by 
Mann Whitney U test.
RESULTS
Method development
HPLC assay
Dithiothreitol was chosen as the reducing agent (to liberate HCySH 
from albumin and the other disulphides) since it is non-hazardous. The final 
concentration chosen (10 mmol/l) was half that used by Andersson®®, 
because higher concentrations lead to gel formation. The procedure was to 
mix 100 pi of 50 mmol/l DTT with 400 pi of EDTA plasma and incubate at 
37°C in a water bath for 15 minutes. One hundred microlitres of 150 g/l 
sulphosalicylic acid was then added to precipitate the protein, before 
centrifugation in a benchtop microfuge. Twenty microlitres of supernatant 
were injected onto a 250 x 4.6 mm octadecyl silica column (Spherisorb ODS- 
2, particle size 5 pm (Jones Chromatography Ltd., Hengoed, UK), with a 10 x 
4.6 mm guard column packed with the same material. The mobile phase 
(flow rate 1 mi/min) consisted of 10 mM sodium dihydrogen phosphate 
adjusted to pH 2.75 with orthophosphoric acid, 15% (v/v) methanol and 12 
mmol/l octane sulphonic acid (Sigma Chemical Co., Poole, UK). The mobile 
phase was not recycled to prevent the accumulation of DTT, which otherwise 
caused a rapid deterioration in the chromatographic separation.
The detector was an ESA Coulochem 5100A (ESA Analytical Ltd., 
Cambridge, UK) and was used with an ESA 5010 coulometric cell. Electrode 
1 (E l) was set at a screening potential of +0.4 V and electrode 2 (E2) set at + 
1.0 V, based on Harvey^®. An ESA 5020 guard cell (+ 1.1 V) was installed 
before the autosampler (model ISS 200, Perkin-Elmer, Norwalk, CT, USA). 
Gilson Unipoint software (Anachem Ltd., Luton, UK) was used to integrate
10
the signal (peak area) measured at E2. HCySH standards (2.5 -  40 pmol/1) 
were prepared from L-homocystine (Sigma Chemical Co., Poole, UK).
Internal quality control was achieved using HCySH-spiked, time-expired, 
fresh, frozen plasma (West Midlands Blood Transfusion Service) at 7 and 20 
pmol/i.
Each component of the mobile phase was independently assessed to 
achieve optimal separation of HCySH from the other components. 
Sulphosalicylic acid v\/as not retained on the column. DTT gave rise to an 
early reduced, and a later oxidised peak. Phosphate concentrations greater 
than 10 mmol/l decreased the retention times of all peaks without changing 
the order in which they eluted. Increasing the concentration of the ion-pairing 
reagent, octanesulphonic acid (OSA), did have an effect on retention times, 
more so on HCySH than on the DTT peaks. At 6 mmol/l OSA, the eluting 
order changed as HCySH was retained on the column longer than the 
oxidised DTT peak. Further increases in the OSA concentration up to 12 
mmol/l improved the separation between HCySH and oxidised DTT. The 
optimal mobile phase pH was found to be 2.75, and allowed HCySH to be 
detected down to 2.5 pmol/1. Increasing the methanol concentration reduced 
the retention times of all the peaks without changing their eluting order. 15% 
(v/v) methanol was chosen for optimal separation within a reasonable run­
time. Typical chromatograms are shown in Figure 2. The purity of the HCySH 
peak was established
Figure 2
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Chromatograms of plasma and a 20 pmol/l aqueous standard. Key; 1, 
sulphosalicylic acid; 2, reduced dithiothreitol; 3, oxidised dithiothreitol; 4, 
homocysteine
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electrochemically by plotting the peak areas of the presumed HCySH peak 
(plasma samples) against those of a pure standard at various E2 applied 
voltages. The correlation coefficient (r^) of the resulting regression line was 
0.995. This shows that the presumed HCySH peak had similar 
electrochemical characteristics to the pure standard and provides some 
evidence of specificity. Recovery experiments from spiked plasma showed 
HCySH recoveries of 97 -100%.
Imprecision data gave intra-assay CV’s of 3.9% at 20 pmol/l (n = 20) and 
2.3% at 50 pmol/l (n = 20). Inter-assay CV’s were 10.7% at 7 pmol/l and 11.0 
% at 20 jLimol/l (both n -  19)^ "^ .
The assay was subsequently improved by the incorporation of an 
internal standard^^. Penicillamine was chosen because it does not occur 
naturally in the body and has a similar structure to homocysteine. 
Refinements were also made to the mobile phase with the substitution of 
diammonium hydrogen phosphate for sodium phosphate. It was found that 
the ammonium ions helped to block residual uncapped silanol groups on the 
column packing, resulting in improved peak symmetry. As before, starting 
with 400 pi of plasma, 100 pi of 50 mmol/l DTT was added to reduce the 
disulphide bonds and liberate the homocysteine, but it also contained 200 
pmol/l penicillamine, as the internal standard. The mobile phase consisted of 
10 mmol/l diammonium phosphate, adjusted to pH 2.58 with orthophosphoric 
acid, 13.75% (v/v) methanol and 12 mmol/l OSA. The method was otherwise 
unchanged as were the detector settings Each component of the mobile 
phase was once again individually adjusted to ensure optimal separation of 
HCySH from the other components, (Table 1). Under these conditions the
limit of detection for HCySH was reduced to less than 0.6 pmol/l. imprecision 
data gave improved intra-assay CV’s of 2.2% at 7 pmol/l and 2.4% at 20 
pmol/l (both n = 20). Inter-assay CV’s were 8.6% at 8,5 pmol/l and 6.8% at 
25 pmol/l (both n = 8). Typical chromatograms are shown in Figure 3.
Table 1
The effect o f varying pH  on peak retention times (min).
DTT DTT
Qh Reduced oxidised HCvSH Penicillamine
3.25 5.7 9.5 a 6.8
3.00 5.6 9.3 6.2 8.5
2.85 5.7 9.4 7.4 10.5
2.75 5.7 9.6 8.6 12.6
2.65 5.7 9.5 b 14.5
2.58 7.3 12.6 16.3 29.0
2.50 6.6 11.2 15.6 26.9
® the HCySH peak co-eluted with reduced DTT 
the HCySH peak co-eluted with oxidised DTT
Figure 3
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Typical chromatograms achieved with a mobile phase consisting of 10 mmol/l 
diammonium phosphate (pH 2.58) containing 137.5 ml/1 methanol and 12 
mmol/l octane sulphonic acid. The flow rate was 1 ml/min. A 1.25 pmol/l 
calibrator; B 40 pmol/l calibrator; C plasma containing 20 pmol/l HCySH.
Peak 1, reduced DTT; peak 2, oxidised DTT; peak 3, HCySH; peak 4, 
penicillamine (internal standard).
Patient Studies
1 Reference Interva!
The modified method with internal standard was adopted for the 
clinical studies and volunteers were recruited from the laboratory staff and 
from patients attending Heartlands hospital without a history of athero­
thrombotic disease to construct a HCySH reference interval. The mean 
HCySH levels for the 38 men and 47 women did not differ significantly (10.3 
± 1.5 V 9.0 ± 1.4 pmol/l, p = 0.10) and are similar to published ranges from 
around the world. However the HCySH levels did
Table 2
Age-related reference interval for plasma total homocysteine
M§,.(yr). mean [sdl (umol/l) 0
20-29 7.87 [1.35] 11
30-39 8.14 [1.26] 10
40-49 8.11 [1.35] 11
50-59 9.93 [1.50] 23
60-69 10.56 [1.46] 22
70-79 11.85 [1.55] 7
One-way analysis of variance shows that the difference between the group 
means is significant (p = 0.046). The single subject aged > 80 years was 
excluded.
16
increase significantly with age, Table 2 and therefore an age-related 
reference interval was constructed. The rate of increase with age was similar 
to that published for a German cohort^®.
2 Homocysteine and microvascular disease
The reference interval was also used in a study to investigate whether 
homocysteine levels were elevated in microvascular disease, with arterial or 
venous retinal vascular occlusive disease (RVOD) being chosen as the 
paradigm. These conditions, although rare, present as sudden-onset 
blindness (with or without pain) and consequently make an ideal study group. 
RVOD has previously been associated with diabetes, hypertension and 
hyperlipidaemia^^ and there have also been case reports that homocysteine 
may be associated with RVOD^®’^ .^ Seventy patients presenting with RVOD 
were recruited from the General and Medical Ophthalmology clinics at the 
Heartlands and Priory Hospitals in Birmingham. Ail subjects underwent 
complete ophthalmological and medical examinations. The diagnosis was 
confirmed by ophthalmoscopy after pupillary dilation and 36 patients were 
diagnosed as having central retinal vein occlusions (CRVO), 24 had a 
diagnosis of branch retinal vein occlusion (BRVO) and the remaining 10 had 
retinal artery occlusions (RAO).
All of the groups had equal male/female ratios and there were no 
significant differences between the RVOD subgroups as regards mean age, 
serum total cholesterol, triglycerides, glucose, cigarettes smoked or ethanol 
intake. The control group were, however, significantly younger than the RVO 
group [51.5 (15.4) yr v 65.6 (12.5) yr, p<G.00Q1] or the RAO group [51.5
17
(15.4) yr v 69.8 (6.7) yr, p<0.0001]. Univariate analysis revealed that 
homocysteine levels were significantly raised in both arterial and venous 
occlusions compared to controls (Table 3). This relationship remained after 
grouping the patients and controls into decades of age.
Table 3
Mean vaiues and standard deviations for age, piasma total 
homocysteine and serum creatinine in patients with retinal vascular
disease and controls.
Age (years) HCvSH(umol/h creatinine(umol/h
controls 51.5 +/- 15.4 9.5 +/- 1.5 105.8 +/- 18.9
RAO 69.8 +/- 6.74* 18.4 +/- 1.5** 115.1 +/-23.7
RVO 65.6+/-12.5" 13.8+/-1.5" 97.7+/-31.1
p<0.0001 V control 
p=0.0002 V control
Multiple linear regression analysis revealed that the presence of 
retinal vessel occlusion (p= 0.0002), serum creatinine (p= 0.001) and age (p=
0.003) were all significantly linked to HCySH levels, while gender was not, 
Table 4.
Subgroup analysis of the RVOD group revealed that those patients 
with CRVO had significantly higher HCySH levels than BRVO (not shown) as 
had patients with RAO. There were no differences between the groups as
regards age, total cholesterol, triglycerides, cigarette smoking or ethanol 
consumption. However, both the mean systolic and diastolic blood pressures
Table 4
Multiple linear regression analysis with log homocysteine as the
dependent variable
B
95% confidence 
intervals for B p value
variable
RVOD 0.119878 0.057825- 0.181930 0.0002
Creatinine 0.003243 0.001348-0.005137 0.001
Age 0.004605 0.001595- 0.007614 0.003
Gender 0.003449 -0.062867 - 0.069766 0.918
B represents the slope of the regression line. 
The multiple R value was 0.607.
were significantly elevated in the BRVO group compared to either the CRVO 
or RAO groups as has previously been reported^^.
3 Homocysteine and peripheral vascular disease (PVD).
An association between PVD and hyperhomocysteinaemia has been 
established in middle-aged men^°. Such patients are not generally 
representative of those with vascular disease, who are typically elderly and
hence may be B vitamin deficient^®’^ ®'^ °. There have been no studies 
performed on homocysteine in such vascular patients.
There was a reported association between hyperhomocysteinaemia 
and neointimai hyperplasia (NIH) in 19 patients with infrainguinal lower limb 
vascular bypass grafts^\ NIH is a form of vein graft stenosis, which may 
develop postoperatively in about 30% of grafts and is due to excessive 
vascular smooth muscle cell proliferation occurring for unknown reasons. The 
endothelium remains intact, but the vessel lumen is narrowed. This study 
investigated HCySH levels in unselected vascular clinic patients with PVD or 
NIH.
PVD was confirmed by clinical examination and an ankle-brachial 
blood pressure index (ABPI) < 0.8. The disease spectrum ranged from mild 
claudication to end-stage critical ischaemia. The presence of NIH in 
infrainguinal vein grafts that had developed critical vein graft stenosis was 
defined by a peak systolic velocity ratio greater than 2.5 after one post­
operative year. All vein grafts had been part of a surveillance programme 
using colour-coded duplex imaging^^.
Clinical and demographic data were obtained. Investigations included 
chest X-ray and electrocardiograph. Fasting biochemistry and haematological 
indices were measured by standard laboratory methodology.
One hundred subjects were recruited: 48 with PVD (male:female 
32:16), 22 with NIH (14:8) and 30 controls (15:15).
The PVD group had varying degrees of ischaemia with resting ABPI 
ranging from 0.21 to 0.7. Twelve patients had critical ischaemia and four had 
had amputations. Three patients also had symptomatic PVD manifest by
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non-disabling claudication and two had asymptomatic disease detected by 
ABPI < 0.8. All patients in the NIH group had infrainguinal vein graft 
bypasses with stenoses producing a peak systolic velocity ratio > 2.5 within 
one postoperative year and all subsequently had angioplasty.
There were no significant differences between the groups in 
haemoglobin, white cell count, platelets, haematocrit, fibrinogen, vitamin B12 
levels, electrolytes, albumin, bilirubin, transaminases, alkaline phosphatase, 
fasting glucose or triglycerides.
There were significant differences between the groups in age, body mass 
index, systolic blood pressure, smoking habit, serum creatinine, total 
cholesterol, HCySH and folate levels, (Table 5). The NIH group was 
significantly older than the controls. Both patient groups had a higher 
percentage of smokers than the control group, even though the percentage 
of smokers in the control group was itself unusually high at 55%. The PVD 
group had significantly higher systolic blood pressures than the controls
Renal function, as indicated by serum creatinine levels, was worse in 
the patient groups compared to controls, and serum total cholesterol levels 
were significantly higher in the NIH group.
HCySH levels in the control group were comparable to the age- 
matched laboratory reference interval (data not shown). The mean HCySH 
level in the PVD group was significantly higher than the level in the control 
group, while the HCySH levels for the NIH group did not differ significantly 
from the controls (Table 6). Serum folate levels were significantly lower in the 
PVD and higher in the NIH groups than in the controls.
Logistic regression analysis confirmed these findings, with peripheral
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vascular disease being related to HCySH levels (table 6) such that the odds
Table 5
Measured parameters, mean (sd), which differ from controls
Controls PVD NIH
Age (years) 65.2 (11.1) 64.6 (10.3) 72.6 (9.5)*
BMI 27.1 (7.0) 25.1 (5.1) 27.5 (6.7)
Smokers (%) 55 88**" 85*
SBP(mmHg) 141.9 (22.8) 152.0 (17.3)* 143.0 (19.8)
Cre (pmol/l) 87 (18) 112 (57)* 133 (48)****
TChol (mmol/l) 4.91 (1.15) 5.52 (1.19) 6.10 (1.04)*
HCySH (gmol/i) 12.3 (1.4) 17.4 (1.7)** 10.6 (1.5)
Folate (ng/l) 5.14 (1.90) 4.26 (1.55)* 7.55 (3.81)*
*p<0.05 'p<0.01 'p<0.001 *"*"p<0.0001
ratio for PVD increased fourfold for each 1 pmol/1 increase in HCySH (95% 
Cl 1.49 -  11.07, p = 0.0061). Fasting glucose levels were also related to 
PVD, with an odds ratio of 1.51 per mmol/l (95% Cl 1 .06 -2 .15 , p = 0.0233). 
Neointimai hyperplasia was found to be related to male sex, haemoglobin 
concentration and serum folate levels, but only weakly and negatively to 
HCySH.
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4 Homocysteine and IHD
IHD is known to be multifactorial in origin and HCySH has been purported to 
be an independent risk factor for IHD which is quantitatively as important as 
smoking^ A variety of other additional risk factors for IHD have been
Table 6
A Logistic regression analysis with peripheral vascular disease as
the dependent variable
Variable B SE_B OR (95% C\) g
log HCySH 14.03 5.11 4.07 (1.49-11.07)* 0.0061
Glucose 0.41 0.18 1.51 (1.06-2.15) 0.0233
Haemoglobin -0.18 0.10 0.83 (0.69-1.01) 0.0578
B Logistic regression analysis with neointimai hyperplasia as the
dependent variable
Variable B SE_B OR (95% Cl)
Male sex 2.16 0.93 8.70 (1.40-54.2) 0.0204
Haemoglobin 0.76 0.35 2.15 (1.09-4.23) 0.0272
Serum folate 0.86 0.41 2.37 (1.05-5.32) 0.0367
log HCySH -7.91 4.24 0.45 (0.20-1.04)* 0.0624
* odds ratio per pmol/l HCySH
B denotes the estimated coefficient used In the analysis
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proposed including lipoprotein (a )^ and angiotensin converting enzyme 
(ACE) genotype^. None of these have yet been proven to be causative and 
most studies have examined each factor in isolation and compared disease- 
free control groups to groups with IHD. This study involved 280 patients who 
underwent coronary angiography at Birmingham Heartlands Hospital Chest 
Pain Clinic. The largest group (110) were those undergoing further 
investigation after myocardial infarction. Eighty patients proved to have no 
angiographic evidence of atheroma and were designated as controls 
because of their good prognosis^^. Power calculations showed that for 
triglycerides and lipoprotein (a), the assays with the poorest precision, 50 
subjects were required for 95% significance at 90% power to demonstrate a 
difference from the controls. All patients had fasting blood samples taken for 
the measurement of serum creatinine, total cholesterol, triglyceride, glucose, 
lipoprotein (a), ACE activity, ACE genotype and total plasma homocysteine. 
Diabetes mellitus was defined using the new World Health Organisation / 
American Diabetic Association criteria as a fasting glucose > 7.0 mmol/l. 
Hypertension was defined as a blood pressure greater than 160/90 mmHg. 
Lipoprotein (a) and ACE activity were measured on a Monarch analyser (IL, 
Warrington, UK) using Randox (Ardmore, UK) and Sigma (Poole, UK) 
reagent kits, respectively. ACE genotyping was kindly perfomed by Dr. F. 
MacDonald of the Women’s Hospital, Birmingham according to the method of 
Cambien^. Table 7 shows the demographic and biochemical data for the 
study population. The control and IHD groups had similar ages, percentages 
of smokers and hypertensives. The proportion of those with diabetes in the 
IHD
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Table 7
Variables measured in the study population
IHD -ve 
(controls)
IHD +ve 
(anaio +ve) p value
Odds ratio 
(95% Cl)
Age, years (sd) 58.5(11.0) 58.4 (9.7) 0.93
Males/females 37/43 152/48 0.002
BP > 160/90 (%) 40.8 37.7 0.74
Smokers (%) 15.8 19 0.73
Diabetes (%) 8.8 16.6 0.2
Glu, mmol/l 5.4 (1.4) 5.8 (1.9) 0.09
Great, pmol/l 103 (20) 114 (38) 0.004 1.99 (1.24-2.74)
M chol, mmol/l) 5.6 (1.2) 6.0 (1.0) 0.034 2.01 (1.17-2.85)
F chol, mmol/l) 6.4 (1.1) 7.3 (1.4) 0.001 3.79 (2.51-5.07)
Trigs, mmol/l) 2.1 (1.1) 2.6 (1.6) 0.002 1.71 (0-3.46)
HCySH, p.mol/1) 10.1 (1.5) 11.5 (1.4) 0.008 1.50 (1.06-1.93)
Lp (a), mg/dl)14.7 (3.5) 17.0 (3.0) 0.39 1.08 (0.57- 1.58)
ACE act, U/l 38.9 (16.6) 38.3 (19.6) 0.8
ACE, II (%) 24.0 25.0 0.99
ACE, DD (%) 20.0 27\4 0.28
Data is presented as mean (sd)
Angio +ve = coronary artery stenosis. BP = blood pressure. DM = diabetes 
mellitus. Glu = fasting glucose. Great = serum creatinine. M chol (F chol) = 
male (female) total cholesterol levels. Trigs = fasting triglyceride levels. 
HCySH = plasma total homocysteine. Lp (a) = lipoprotein (a). ACE act = 
angiotensin converting enzyme activity. ACE, II (DD) = ACE genotypes.
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Table 8
The association between some proven and putative risk factors and 
acute myocardial infarction (AMI).
Males
Cholesterol, mmol/l 
Triglycerides, mmol/l 
HCySH, gmol/l
Controls 
(n = 37)
5.6 (1.2)
2.3 (1.4)
10.9(1.6)
AMI
(n -  88)
6.0 (0.9) 
2.7 (1.4)
11.1 (1.3)
p value 
0.044 
0.17 
0.72
B Females
Cholesterol, mmol/l 
Triglycerides, mmol/l 
HCySH, p.mol/1
Controls 
(n = 43)
6.4 (1.1) 
1.9 (0.7)
9.4 (1.4)
AMI
(n = 22)
7.0 (1.7)
3.0 (2.5) 
11.9 (1.4)
p value 
0.10 
0.07 
0.016
Data is presented as mean (sd)
group, although almost double that in the control group, was not statistically 
significantly different and the mean serum glucose values were almost 
identical in the two groups. As expected, there was a male preponderance in 
the IHD group with significantly fewer females having proven IHD. Serum 
total cholesterol, creatinine, triglyceride and plasma HCySH levels were
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Table 9
The association between some proven and putative risk factors and
stable angina
A Males
Cholesterol, mmol/l 
Triglycerides, mmol/l 
HCySH, |Limol/l
Controls 
(n = 37)
5.6 (1.2)
2.3 (1.4)
10.9 (1.6)
Angina 
(n = 57)
6.1 (1.0)
2.2 (1.2)
12.1 (1.5)
p value 
0.017 
0.66 
0.26
B Females
Cholesterol, mmol/l 
Triglycerides, mmol/l 
HCySH, jj.mol/1
Controls 
(n = 43)
6.4 (1.1) 
1.9 (0.7)
9.4 (1.4)
Angina 
(n = 24)
7.5 (1.1)
3.2 (1.6)
11.2 (1.4)
p value 
< 0.001 
0.001 
0.07
Data is presented as mean (sd)
significantly elevated in the IHD group, but lipoprotein (a), ACE levels and 
ACE genotype were not significantly different between the two groups. Apart 
from serum cholesterol, there were no sex differences in the levels of the 
measured variables.
Further analysis focussed on HCySH and the established risk factors 
cholesterol and triglycerides. Table 8 details the associations between these 
risk factors and acute myocardial infarction in males and females. Total 
cholesterol, as expected, was significantly related to acute myocardial
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infarction in men, but not women. Only HCySH was linked to myocardial 
infarction in women. In contrast, table 9 shows that cholesterol was 
associated with stable angina in both sexes, serum triglycerides were linked 
to angina in females only and HCySH was not associated with angina in 
either sex.
Table 10
The association between some proven and putative risk factors and
coronary artery occlusions
A Males
Controls 
(n = 37)
Occ -ve 
(n = 77)
Occ +ve 
(n = 68) p value
Cholesterol, mmol/l 5.6 (1.2) 6.1 (0.9)* 6 .0 (10 ) 0.026
Triglycerides, mmol/l 2.3 (1.4) 2 .4 (13 ) 2.5 (1.4) ---
HCySH. pmol/l 10.9 (1.6) 11.4(1.4) 118(1.4) ---
B Females
Cholesterol, mmol/l 
Triglycerides, mmol/l 
HCySH, pmol/l
Controls 
(n = 43)
Occ -ve 
(n = 27)
Occ +ve 
(n = 19) p value
6.4 (1.1) 7.3 (1.1)* 6.8 (1.3) 0.001
1.9 (0.7) 3.5 (2.3)* 2.2 (0.8) 0.002
9.4 (1.4) 10.6 (14) 12.2 (1.5)* 0.019
Data is presented as mean (sd)
Occ +ve (-ve) = coronary artery occlusion present (or absent). 
* denotes significantly different from controls.
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When the angiographic findings were included in the analysis, cholesterol 
levels were linked to coronary artery occlusions (table 10) in both sexes, but 
triglycerides and HCySH were related to occlusions in female patients only.
Table 11
The association between risk factors and the number of coronary
arteries involved
Males
Cholesterol, mmol/l 
Triglycerides, mmol/l 
HCySH, jj.mol/1
B Females
Cholesterol, mmol/l 
Triglycerides, mmol/l 
HCySH, }.imol/l
Controls 
(n = 37)
1 vessel 
(n = 41)
2 or more 
(n = 108) p value
5 .6 (12 ) 6.0 (0.9) 6 .0 (10 )* 0.033
2.3 (14 ) 2 .4 (13 ) 2.4 (1.3) ---
10.9 (16) 111 (1.4) 11.6 (1.4) ---
Controls 
(n = 43)
1 vessel 
(n = 21)
2 or more 
(n = 27) p value
6 .4 (11 ) 6 .9 (10 ) 6 .8 (13 )* 0.002
19 (0.7) 3.0 (2.2) 3.2 (2.0)* 0.003
9.4 (1.4) 10.6 (14) 12.3 (1.4)* 0.003
Data is presented as mean (sd)
* denotes significantly different from controls.
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A similar picture was seen for the number of atheromatous coronary arteries, 
table 11, where cholesterol was significantly elevated in patients of either sex 
with 2 or more atheromatous coronary arteries. Plasma HCySH again was 
elevated only in females and only significantly raised in those with 2 or more 
diseased vessels. Serum triglycerides were also higher, but only in females, 
and were significantly elevated regardless of the number of vessels involved.
Table 12
The association between risk factors and the number of coronary
arteries involved
B SE OR 95% Cl sig
Sex (F) -5.068 0.179 0.006 0.004-0.009 <0.001
Cholesterol 0.523 0.157 1.69 1.24-2.30 <0.001
Log HCySH 2.526 1.078 1.52 1.03-55.2 0.019
B
Cholesterol 0.440 0.210 1.55 1.03-2.34 0.036
C
Cholesterol 0.762 0.254 2.14 1.30-3.53 0.003
Age -0.071 0.030 0.93 0.88-0.99 0.018
Log HCySH 4.178 1.959 1.29 1.04-35.4 0.033
OR = odds ratio. 95% Cl = 95% confidence intervals. Sig = significance. Log 
HCySH = logarithm of plasma total homocysteine concentration. B denotes 
the estimated coefficient used in the analysis
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Multivariate analysis (logistic regression) of all measured variables was 
performed with IHD as the dependent variable and the results are shown in 
table 12. Table 12A demonstrates that IHD is related to male sex, cholesterol 
and homocysteine levels. A 1 gmol/l increase in HCySH concentration results 
in a 1.52-fold (95% Cl 1.03 to 55.2, p= 0.019) increase in the odds ratio for 
IHD. Table 12B confirms that only cholesterol levels were significantly linked 
to IHD in males, whereas HCySH contributes to IHD in females (table 12C), 
where a 1 pmol/l increase in HCySH increases the odds ratio for IHD by a 
factor of 1.29 (Cl 1.04 -35.4, p= 0.033).
5 Homocysteine and lipoprotein oxidation
Native low density lipoprotein (LDL) is relatively non-atherogenic but 
oxidative modification renders it atherogenic^®. Auto-oxidation of thiols 
generates oxygen free radicals that may result in oxidative modification of 
LDL. Cellular LDL oxidation in vitro has been found to require thiols it is 
thought that thiols may promote LDL oxidation by generating reactive oxygen
species. Studies have shown that superoxide (02‘ )^ ,^ hydrogen peroxide
(H2 0 2 )^°’^ '^^° and hydroxyl radical (OH')^^'^^ can be produced by the
oxidation of thiols and that reduced HCySH is rapidly oxidised in plasma to 
give homocystine and the mixed disulphide (cysteine-homocysteine)"^®. 
Heinecke et a/."^ observed that superoxide dismutase (SOD) prevented a 
copper (II) and cysteine dependent increase in macrophage degradation of
labelled LDL, implicating O2"" in lipid peroxidation. However, not all 
workers have found that thiols promote the transition metal ion (TMI)
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catalysed oxidative modification of LDL is usually considered to be
the main atherogenic lipoprotein found in plasma. Agarose gel 
electrophoresis of the lipoprotein fraction isolated by the ultra-centrifugation 
technique employed in the present study showed that, although it contained 
predominantly LDL, there was also some contamination with VLDL. It has 
recently been reported that VLDL is also susceptible to copper (II) catalysed 
oxidation, and as with LDL, the reaction produces conjugated dienes with lag 
phases approximately double those observed with LDL"* .^ It has been 
proposed by one group that VLDL might also be involved in the development 
of atherosclerotic plaques, possibly depositing larger quantities of lipid into 
the developing foam cells than would LDL"^ ® The presence of VLDL in the 
preparation therefore, would not appear to prejudice the significance of the 
findings.
We observed that with freshly isolated LDL, both 20 pmol/l HCySH 
and the same concentration of cysteine (Cys) acted as anti-oxidants by 
significantly Increasing the lag times of LDL oxidation (calculated as in 
McDowell et a/^ ®) compared to incubations without added thiol (>180 min 
versus 17.5 min (8-60), [median (range)], n=10; p<0.0001 for HCySH and
88.5 min (66-123) versus 9 min (4-19), n=6; p<0.001 for Cys). With LDL 
aged by storage at 4°C, 20 pmol/l HCySH acted as a pro-oxidant, shortening 
lag times (5 min (4 -17) v 7 min (6-23), median (range), n=10; p<0.05), 
whereas 20 jj.mol/1 Cys had no significant effect (6 min (5-17) v 6 min (4-7), 
n=6; NS). Examples of the effect of HCySH and Cys on the kinetics for LDL 
oxidation are given in Fig. 4.
Figure 4
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Copper (II) catalysed LDL oxidation (conjugated diene formation) on fresh 
and aged LDL. 20 pmol/l homocysteine, dotted lines; 20 pmol/l cysteine, solid 
lines; control, solid lines with filled triangles.
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The effects of HCySH and Cys on LDL oxidation were found to be 
concentration dependent. The concentration range for HCySH and Cys used 
in this study was chosen to include the plasma reference range for HCySH 
and to extend up to that found in moderate hyperhomocysteinaemia. On day 
1 the lag time of LDL oxidation was the shortest in the incubation without 
HCySH (Fig. 5a). inclusion of 2.5 pmol/l HCySH increased the lag time, 
whilst 10 and 20 pmol/1 HCySH prevented oxidation over the three hour study 
period. By day 2, the incubations with the lowest concentration of HCySH 
had a similar lag time to the incubation without HCySH. On day 3 oxidation 
occurred for the first time in incubations containing 10 pmol/l and 20 p.mol/1 
HCySH, but with a longer lag time than in the absence of HCySH. By day 4 
all incubations containing HCySH had a shorter lag time than in the absence 
of HCySH, with the shortest lag time being seen with the highest 
concentration of HCySH. In the case of Cys the lag time of LDL oxidation 
was shortest in the incubation without Cys on day 1 (Fig. 5b). Inclusion of
2.5 pmol/l, 10 jj.mol/1 and 20 pmol/l Cys increased the lag time in a 
concentration-dependent fashion, however, unlike HCySH, oxidation still 
occurred at all concentrations within the three hour period of the study. On 
day 2 the lag time for 2.5 pmol/l and 10 pmol/l Cys was similar to that in the 
absence of Cys whilst the lag time in the presence of 20 pmol/I was slightly 
longer. On day 3 the lag time in the presence of all concentrations of Cys 
was the same. Cys was not studied on day 4 as previous studies had shown 
that it failed to become a pro-oxidant.
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Variation in the lag phases for copper(ll) catalysed oxidation of LDL at 
various thiol concentrations, with fresh or aged LDL. Key: white bars, no thiol; 
light gray bars, 2.5 pmol/l thiol; dark grey bars, 10 pmol/l thiol and black bars, 
20 pmol/l thiol. Graph a shows the effects of homocysteine, while b 
represents the effects of cysteine.
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The vitamin E concentration in three LDL preparations was measured 
according to the method of Thurnham et a P  by Mr. D. Mayoss-Hurd, City 
Hospital, Birmingham to see if it decreased following storage at 4°C. The 
vitamin E concentration in freshly isolated LDL was 16.0 nmol/mg protein (8.7 
-  22.7), median (range). On day 3 this had declined to 11.2 nmol/mg protein 
(3.2 -  14.7), median (range).
To investigate whether auto-oxidation of thiols was a possible 
mechanism for the copper (II) catalysed oxidation of LDL reduced and total 
HCySH were assayed in the incubation mix. Reduced HCySH was almost 
immediately oxidised, irrespective of whether LDL was present or not. In the 
presence of copper (II) ions only 25% of the HCySH remained in the reduced 
form at zero minutes and by 120 minutes, reduced HCySH could no longer 
be detected. All of the reduced HCySH in these samples was oxidised to 
homocystine as there was no significant decline in the amount of total 
HCySH (after reduction with DTT) measured in parallel. The addition of 
reduced HCySH to PBS again resulted in its oxidation, but at a slower rate 
than in the presence of copper (II) ions, with 68% of the reduced form 
present at zero minutes and 39% at 120 minutes.
6 Effect o f folic acid on lipoprotein oxidation
Supplemental folic acid has been shown to significantly reduce plasma 
HCySH levels. As little as 400 p.g per day Is effective in reducing HCySH 
levels^’’ and higher doses do not appear to result in any greater reductions^. I 
investigated the effect of 4 weeks treatment with 400 pg of folic acid on the
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lipoprotein lag phases of volunteers. The subjects were healthy laboratory 
staff who had previously had their HCySH measured for the reference 
interval study. Seven subjects from the highest quartile (Q4) of HCySH levels 
and 6 from the lowest quartile (01, controls) agreed to participate. The lag 
phase for the copper (II) catalysed oxidation of freshly prepared LDL was 
measured by the methods described above. The 04 subjects had the 
shortest lag phases for LDL oxidation, mean 37.1 min (sd 15.7 min) versus a 
mean of 51.9 (21.0) min for the controls. The subjects were given 400 pg 
folic acid per day (the controls received no intervention). After 4 weeks the 
lag phase for LDL oxidation was re-measured in both groups. Data from 1 
control was lost due to a centrifuge failure. While there had been no 
significant change in the length of the lag-phase in the control group, 45.0 
(8.5) min; p = 0.34, there was a significant increase in the length of the lag 
phase, Figure 6, for the folate-treated group, 49.4 (20.5) min; p = 0.018 v day
1. The average increase was 33.2%, compared to -13.3% for the controls, 
making the length of the lag-phase comparable in the 2 groups. Over the 
same period there had been a mean reduction in the HCySH levels of the 
folate treatment group of 23.0%, in agreement with the literature.
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Figure 6
The Effect of Folate on LDL 
oxidation
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Copper (II) catalysed LDL oxidation at day 1 and day 28 of the experiment. 
The control subjects in quartile 1(Q1) are shown in green, while the subjects 
from quartile 4 (Q4), who took folic acid are depicted in red. The mean lag 
phase and 1sd are shown in black.
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DISCUSSION
A sensitive HPLC method for measuring plasma total homocysteine 
has been developed. HPLC was chosen because the other methods for 
measuring HCySH are either expensive (GC-MS) and not readily available in 
routine clinical laboratories, or too insensitive (aminoacid analysers). 
Fluorometric HPLC methods for measuring HCySH often have very high 
background fluorescence and utilise toxic fiuorophores and other hazardous 
chemicals such as sodium borohydride and p-mercaptoethanol. This limits 
their usefulness to a hospital laboratory. HPLC using electrochemical 
detection appeared to offer a better solution. Gold/mercury electrodes are 
easily ‘poisoned’ and require regular regeneration to restore activity, 
whereas coulometric detection has the advantage of familiarity, as it is 
already widely used by hospital laboratories measuring urine 
catecholamines, therefore there is an available pool of expertise and 
equipment to draw on. Dithiothreitol (DTT) was chosen as the reducing agent 
as it is safer than sodium borohydride and does not require to be handled in 
a fume-cabinet, unlike p-mercaptoethanol. The concentration of DTT used 
v^as halved from 20 mmol/l in the original paper^^ to avoid gel formation and 
to reduce the background signal. Even lower concentrations were tried (down 
to 5 mmol/l) but concern about potential Incomplete total HCySH release 
resulted in 10 mmol/l being used in all the experiments described in this 
thesis. Even at this DTT concentration, the background was so low that it 
was possible to accurately determine HCySH concentrations as low as 0.625 
pmol/l in aqueous solutions.
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Using this HPLC method, I investigated whether there was a 
relationship between HCySH levels (and other proposed risk factors) and 
IHD in high-risk subjects and the strengths of any relationships. We studied 
ACE levels and genotype, lipoprotein (a) and plasma total HCySH along with 
established risk factors to see if the newer analytes were linked to proven 
coronary artery disease in a population of selected high-risk individuals. All of 
the patients were undergoing investigation at a Chest Pain Clinic and the 
controls consisted of a sub-group of those patients with angiographically 
normal coronary arteries, a group known to have a good prognosis 
(cardiological syndrome X)^^. A criticism of previous studies investigating the 
relationship between HCySH and IHD has been the selection of a disease- 
free control group, which can accentuate any differences in HCySH (or other 
analyte) levels and introduce bias. The control group in this study was, 
therefore, very closely matched to the subjects.
Univariate analysis revealed that the control and IHD groups were well 
matched for age, hypertension, smoking and glycaemic control. There was 
the anticipated male predominance in the IHD group where diabetes mellitus 
was also more common, although not significantly so. Serum cholesterol and 
triglycerides were both significantly elevated in the IHD group as expected, 
but there were no significant differences in ACE activity, ACE genotype or 
lipoprotein (a) levels. Plasma total HCySH levels were significantly raised in 
the IHD group suggesting that this putative risk factor may be linked to IHD, 
whereas the evidence does not support a link between lipoprotein (a), ACE 
activity or genotype and IHD. These results contradict some previous
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reports^^’^  but others have questioned the strength of the proposed link 
between Lp(a)^^ and ACE genotype^^ and IHD.
Further univariate sub-group analysis concentrated on HCySH, cholesterol, 
triglycerides and gender, because of the significant sex difference seen for 
total cholesterol levels. These analyses revealed that cholesterol levels in 
men and HCySH levels in women were significantly elevated in acute 
myocardial infarction. Cholesterol levels in both sexes were raised in stable 
angina as were triglycerides in females but there was no significant link 
between angina and HCySH in either sex. A comparison of the angiographic 
findings with the results revealed that cholesterol was higher in patients of 
either sex with a coronary artery occlusion, but that HCySH and triglycerides 
were only elevated in female patients with occlusions. When the levels of the 
various analytes are compared to the number of atheromatous coronary 
arteries, cholesterol is significantly raised in patients of both sexes with more 
than 1 vessel involved. Triglycerides are additionally elevated in women as is 
HCySH. Taken together these findings suggest a link between HCySH and 
acute thrombotic events (myocardial infarction or occlusion) in females with 2 
or more atheromatous coronary arteries. There is a consistent lack of 
association between HCySH levels and IHD in males in contrast to some 
previous studies^^’^ "^ .
Multivariate analysis confirmed the link between HCySH and IHD with a 1.5- 
fold increase in the odds ratio for IHD for each pmol/l increase in HCySH.
This was similar to the 1.7-fold increase seen per mmol/l serum total 
cholesterol. The link between IHD and HCySH appeared to exist particularly
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in females, where the odds ratio increased 1.3 times for each i^mol/l increase 
in HCySH, but not in males.
Whether the link between HCySH levels and I HD is causative is still a matter 
of debate. Prospective studies of HCySH and acute myocardial infarction 
have given conflicting results^ '^^" '^^ ’^^ ,  but these studies have almost 
exclusively involved males and our results suggest that HCySH is more 
closely linked to myocardial infarction in females. Indeed, in our study, 
HCySH was the only analyte significantly linked to myocardial infarction in 
women.
Multivariate analysis confirmed the link between HCySH and IHD. HCySH is 
known to increase both with age^ '^^® and serum creatinine levels^'^^. The link 
between HCySH and the number of vessels affected is in agreement with 
Nygârd et a/^.
In conclusion, HCySH, but not lipoprotein (a), ACE activity or ACE genotype 
is associated with IHD in a high-risk group who underwent coronary 
angiography. Further, HCySH appears to be particularly linked to thrombotic 
disease and IHD in females. Future prospective studies should include more 
females to confirm the hypothesis that HCySH causes IHD.
Previous studies have shown that total plasma homocysteine levels 
are elevated in selected younger patients (aged less than 50 years) with 
peripheral vascular disease^ or neointimal hyperplasia^. We studied a more 
typical vascular clinic population to investigate whether hyper- 
homocysteinaemia was related to vascular disease in an un selected (and 
therefore older) vascular clinic population.
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The sex ratios of the groups were not identical, but as post­
menopausal women have been found to have similar homocysteine levels to 
men of the same age^^, this was not considered important. The study groups 
had a significantly higher proportion of smokers than the control group. Both 
groups also had significantly higher serum creatinine values than controls 
and the NIH group was significantly older. Surprisingly, perhaps, only the NIH 
group had significantly higher total cholesterol levels than the controls, there 
being only a non-significant trend (p= 0.08) towards higher cholesterol levels 
in the PVD group. The PVD group had significantly higher HCySH levels than 
the controls and NIH group. The difference between the means was 
surprisingly large at 5.1 pmol/l (141% higher than the control mean). Other 
studies linking HCySH to atherosclerotic disease have usually only shown a 
1 -  3 pmol/l difference from controls. The negative association between 
hyperhomocysteinaemia and NIH contrasts with previous reports and is even 
more surprising considering the age of the NIH patients. HCySH levels are 
known to increase by approximately 1 pmol/l per decade^^ and therefore the 
mean HCySH level in the NIH group would be expected to be at least 0.5 
pmol/1 higher than the controls instead of 1.6 pmol/l lower. Folate deficiency 
has been implicated in the pathogenesis of hyperhomocysteinaemia, so the 
differences in HCySH between the PVD and NIH groups may be a reflection 
of the serum folate levels in each group. This also implies that HCySH is not 
involved in the pathophysiology underlying the development of NIH, despite a 
previously reported link^\
When all the parameters were included in the multivariate analyses, 
HCySH was shown to be closely linked to PVD with an odds ratio of 4 for
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each 1 |umoI/l increase. The fasting glucose level was also positively linked to 
PVD with an odds ratio of 1.5 per mmol/l. Diabetes mellitus is known to be an 
independent risk factor for peripheral vascular disease and these results 
suggest that HCySH may also be an important independent risk factor for the 
development of PVD.
Male sex was the strongest predictor of NIH with an odds ratio of 
almost 9, while haemoglobin and folate levels each gave odds ratios of 
around 2. HCySH was negatively associated with NIH, in keeping with the 
univariate analysis, but narrowly failed to reach significance (p = 0.0624).
In summary, HCySH levels are significantly elevated in 
atherosclerotic vascular disease in a typical, elderly patient population, the 
association is particularly strong for PVD and may be causative. There was 
no association between HCySH and NIH, in contrast to earlier reports.
It is known that the risk factors for retinal vascular disease (RVOD) are 
similar to the risk factors for macrovascular disease. Therefore it was 
possible that HCySH might be linked to the development of microvascuiar 
disease as well as macrovascular disease. We demonstrated that fasting 
plasma total HCySH levels are significantly elevated RVOD. The 
homocysteine levels seen in our controls are similar to those reported for 
elderly German subjects^’’^^  again suggesting that there is a general effect of 
age on homocysteine metabolism. One suggestion, based on tissue culture 
experiments with cystathionine p-synthase, is that there may be an decline in 
enzyme activity with age^^^\
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The subgroup analysis shovv/ed that the HCySH levels were highest in 
RAO, and lowest in BRVO. As previously reported, the BRVO group were 
significantly hypertensive compared to the other groups and this has been 
proposed as the main cause for branch retinal vein occlusions^®^ In this 
study, we found that the HCySH level in BRVO was still significantly higher 
than in the controls (12.2 v 9.5 umol/l; p=0.001) despite being lower than the 
levels found in CRVO (15.0 umol/l) or RAO (18.4 umol/l). This is the first 
study to demonstrate a link HCySH and microvascuiar disease and suggests 
that HCySH should be considered as an independent risk factor for retinal 
vascular disease and an additional risk factor to hypertension in BRVO.
Although there is good epidemiological evidence that links the plasma 
concentration of HCySH to the development of both athero-thrombotic 
diseases, the underlying pathological mechanisms remain uncertain. I 
investigated whether the atherogenic potential of LDL was influenced by 
HCySH and found that HCySH may have both anti-oxidant and pro-oxidant 
effects on LDL oxidation, and that this may contribute to the pathological 
effects seen in hyperhomocysteinaemia. Using freshly isolated LDL replete 
with vitamin E, HCySH and Cys both acted as anti-oxidants. However, after 
ageing LDL by storage at 4°C, HCySH became a pro-oxidant whereas Cys 
had no significant effect. Figure 7 proposes an explanation for the effect of 
thiols on the Cu (II) catalysed oxidation of LDL. The anti-oxidant effect may 
result from auto-oxidation of thiols, reducing vitamin E thereby maintaining its 
anti-oxidant properties. It has been shown that blocking thiol groups on 
apolipoprotein B with MAL6 enhances the rate of vitamin E depletion^^. The
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Figure 7
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Legend Oxidation of the free thiol group in the presence of 
vitamin E (a) results in reduction of vitamin E. In the absence of vitamin E the 
electrons are donated to molecular oxygen or copper II ions to generate 
hydroxyl radicals.
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pro-oxidant effect may only be observed when vitamin E has been partially or 
wholly depleted, when electrons may be transferred to molecular oxygen, 
generating radicals which participate in lipid peroxidation by Fenton-like 
reactions^^ or to copper (II) ions thereby reductively activating them. ThiyI 
radicals (formed from the reaction of thiols with transition metal ions) are also 
able to directly oxidise PUFA®°, it is possible that in the absence of vitamin E 
these may persist for longer. A requirement for reduced thiols has been 
shown by Heinecke et aL'^, who observed that copper (11) catalysed lipid 
peroxidation was increased by the inclusion of Cys and HCySFl but not by 
the presence of homocystine or cystine with their oxidised thiol groups.
Cysteine was a less potent anti-oxidant than HCySH and unlike 
HCySH failed to become a pro-oxidant. Differences in the effect of HCySH 
and Cys on LDL oxidation have been observed previously'^''^®’®^  and it is 
possible that Cys is less susceptible to auto-oxidation than HCySH. Thus Cys 
would be a less potent anti-oxidant and pro-oxidant than HCySH.
Andersson et concluded that the half-life for reduced HCySH in plasma 
was shorter than that of reduced Cys, but this has not been confirmed®^. 
Chain length may affect the redox activity of thiols. Increasing the chain 
length between the thiol group and charged groups has been found to 
enhance the ability of thiyi radicals to oxidise polyunsaturated fatty acids and 
thus the HCySH radical would be a better oxidant agent than the Cys 
radical®^.
The relevance of the pro- and anti-oxidant effects of HCySH on 
atherosclerosis in vivo is unknown. These observations imply a more 
complicated relationship than has been proposed to date and a potential
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interaction with vitamin E. Perhaps there is an interplay between 
hyperhomocysteinaemia and small, dense LDL, which is known to be 
atherogenic and is depleted in vitamin E, that increases the risk of athero- 
thrombosis. Whereas the same HCySH level in a subject with normal LDL 
and lipoprotein vitamin E levels would not increase the subject’s 
cardiovascular risk.
I tested the hypothesis that LDL oxidation would be responsive to 
alterations in HCySH levels by giving folate supplements to a group in the 
highest quartile for HCySH. After 4 weeks of 400 pg folate daily, the mean 
HCySH level had fallen by 23% and the lag phase for LDL oxidation was 
33.2% higher than on day 1, p -  0.018. This resulted in the length of the lag 
phase becoming comparable to the values in the control group.
As yet there are no published prospective trials of the treatment of 
hyperhomocysteinaemia on coronary heart disease events, and the evidence 
from those trials of vitamin E supplementation has been disappointing. It is of 
interest that a recent trial of vitamin E therapy on CHD events in those with 
endstage renal failure®^, a group of patients known to have particularly high 
homocysteine levels, showed large reductions in the risk of CHD, whilst other 
trials have shown little®"^  or no benefit®^. Homocysteine was not measured in 
any of these studies, and we suggest that future studies should allow for a 
potential interaction between HCySH, vitamin E and LDL oxidation.
In conclusion, this thesis documents a novel HPLC method using 
couiometric detection to measure plasma total homocysteine in unselected
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patients attending hospital outpatient clinics with various atherothrombotic 
conditions more suited to hospital laboratories than other available HPLC 
methods.
Using this method, HCySH levels were for the first time shown to be elevated 
in microvascuiar disease^^ (subsequently confirmed by Cahill et aP ) in 
addition to macrovascular disease. HCySH levels were also found to be 
linked to IHD in women, but not in men, which might help to explain why the 
largely male prospective studies have generally failed to link HCySH levels to 
the development of IHD. The association between hyperhomocysteinaemia 
and PVD was confirmed, but the puzzling link to neointimal hyperplasia was 
disproved. I have also attempted to investigate why HCySH might be 
atherogenic through its ability to promote free radical production in vitamin E 
depleted lipoproteins resulting in oxidised LDL formation. Finally, the results 
of a pilot study, indicated that low dose folate consumption not only reduced 
HCySH levels, but also resulted in the production of LDL that was more 
resistant to oxidation.
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